Saturday 17 October 2026
Export FBLG’s income statement to Excel — free account
FibroBiologics Inc.
FBLG Healthcare Biotechnology
In the quarter to June 2026, EPS grew 72.5% and free cash flow grew 21.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.95
0.05
−5.00%
Follow FBLG
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 21.56 | 4.40 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 1,100.00 | 46.70 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 10 | 10 | 13 | 15 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | (2) | (5) | (16) | (11) | (19) | |||||
| EBT margin, % | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | (2) | (5) | (16) | (11) | (19) | |||||
| Depreciation | — | — | — | — | — | — | 0 | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | (3.63) | (13.60) | (6.80) | (8.40) | |||||
| Cash flow | — | — | — | — | — | 0.00 | (2.88) | (4.53) | (7.24) | (7.34) | |||||
| Capex | — | — | — | — | — | — | 0.00 | (0.35) | (0.11) | (0.12) | |||||
| Free cash flow | — | — | — | — | — | 0.00 | (2.88) | (4.89) | (7.35) | (7.46) | |||||
| Book value | — | — | — | — | — | 0.00 | (2.83) | 0.89 | 1.66 | 2.76 | |||||
| Shares, m | — | — | — | — | — | — | 1 | 1 | 2 | 2 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (1) | (4) | (6) | (12) | (16) | ||||
| Capex | — | — | — | — | — | — | — | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | (1) | (4) | (7) | (12) | (17) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | (1) | (4) | 0 | 2 | 5 | ||||
| Total debt | — | — | — | — | — | — | — | — | 9 | — | |||||
| Net debt | — | — | — | — | — | 0 | (2) | (9) | (5) | (5) | |||||
| Shareholders’ equity | — | — | — | — | — | (1) | (4) | 1 | 3 | 6 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | (193.54) | (228.99) | (78.97) | (143.08) | ||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (824.53) | |||||
| ROE | — | — | — | — | — | 0.00 | 193.76 | 1,389.57 | (559.73) | (419.44) | |||||
Negative figures in brackets.
Charts ten years each
FibroBiologics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BCLI Brainstorm Cell Therapeutics Inc. | $7.0M | — (loss-making) | — | — | n/m | +74.44% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR | $7.0M | — (loss-making) | — (loss-making) | −39.66% (below 0%: shrinking) | n/m | +5.08% (above 0%: growing) | (422.22%) | (2,437.96%) | Compare |
| NIKI Niki BioSolutions, Inc. | $6.9M | — (loss-making) | 31.9× | −32.36% (below 0%: shrinking) | +69.51% (above 0%: growing) | +58.14% (above 0%: growing) | (154.22%) | 0.00% | Compare |
| AIM AIM ImmunoTech Inc. | $6.8M | — (loss-making) | — (loss-making) | +4.00% (above 0%: growing) | n/m | −167.46% (below 0%: shrinking) | 80.77% | (13,511.54%) | Compare |
| SYBX Synlogic, Inc. | $6.7M | — (loss-making) | — (loss-making) | −95.40% (below 0%: shrinking) | n/m | −277.87% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| FBLG FibroBiologics Inc. | $6.7M | — (loss-making) | — | — | n/m | +21.59% (above 0%: growing) | — | 0.00% | |
| ACXP Acurx Pharmaceuticals, Inc. | $6.5M | — (loss-making) | — | — | n/m | −2.36% (below 0%: shrinking) | — | 0.00% | Compare |
| TCRT Alaunos Therapeutics, Inc. | $6.4M | — (loss-making) | — (loss-making) | +200.00% (above 0%: growing) | n/m | +57.20% (above 0%: growing) | 100.00% | 0.00% | Compare |
| EVGN Evogene Ltd. | $6.3M | — (loss-making) | — (loss-making) | −35.02% (below 0%: shrinking) | n/m | +17.72% (above 0%: growing) | 40.63% | (738.62%) | Compare |
| Median of peers | $6.7M | — | — | −33.69% | — | +11.40% | 40.63% | 0.00% |
FibroBiologics Inc. (FBLG) key facts
- FibroBiologics Inc. (FBLG) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, FBLG traded at $0.95, a market capitalization of $6.7 million.
- Return on equity was −419.4% and debt-to-equity 0.00.
FibroBiologics Inc. (FBLG) Latest News
No news at this impact. Lower the threshold for more.